RUNX3 is inactivated by promoter hypermethylation in malignant transformation of ovarian endometriosis

Guo,Cuishan; Ren,Fang; Wang,Danbo; Li,Yan; Liu,Kuiran; Liu,Shuang; Chen,Peng

doi:10.3892/or.2014.3524

RUNX3 is inactivated by promoter hypermethylation in malignant transformation of ovarian endometriosis

Authors:
- Cuishan Guo
- Fang Ren
- Danbo Wang
- Yan Li
- Kuiran Liu
- Shuang Liu
- Peng Chen
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Shengjing Hospital Affiliated to China Medical University, Shenyang, Liaoning 110004, P.R. China
Published online on: October 3, 2014 https://doi.org/10.3892/or.2014.3524
Pages: 2580-2588

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the role of epigenetic inactivation of the runt-related transcription factor 3 gene (RUNX3) in the malignant transformation of ovarian endometriosis. Samples obtained by microdissection and scraping included 30 malignant ovarian endometriotic cyst tissues and 30 corresponding eutopic endometrium tissues from the endometriosis-associated ovarian carcinoma (EAOC) group, 19 benign ovarian endometriotic cyst tissues and 22 corresponding eutopic endometrium tissues from the endometriosis (EM) group and 22 normal eutopic endometrium tissues from the control endometrium (CE) group. RUNX3 methylation status was determined by methylation-specific PCR and bisulfite sequencing, while levels of RUNX3 and ERα protein expression were evaluated using immunohistochemistry. The percentage of RUNX3 methylation and negative RUNX3 protein expression in the malignant ovarian endometriotic cysts from the EAOC group was significantly higher than that in the benign ovarian endometriotic cysts from the EM group. The percentage of RUNX3 methylation and negative RUNX3 protein expression in the eutopic endometrium from the EAOC group was significantly higher than that in the EM and CE groups. An inverse correlation between positive RUNX3 protein expression and methylation was observed and a positive correlation was shown between RUNX3 methylation and ERα protein expression. In the malignant ovarian endometriotic cysts from the EAOC group, there was no significant correlation between methylation frequency of the RUNX3 gene and histological type. However, the percentage of RUNX3 gene methylation was significantly higher in the tissue samples from patients with surgical stage IC EAOC than the percentage in patients with stage IA and IB disease. These results suggest that RUNX3 inactivation by promoter hypermethylation plays a role in the progression of malignant transformation of ovarian EM and is closely related to estrogen metabolism. Negative protein expression and abnormal RUNX3 methylation in the eutopic endometrium could be used as diagnostic markers in patients with ovarian EM who may be at an increased risk of developing EAOC.

View Figures

View References

1	Bulun SE: Endometriosis. N Engl J Med. 360:268–279. 2009. View Article : Google Scholar : PubMed/NCBI
2	Sampson JA: Endometrial carcinoma of the ovary arising in endometrial tissue in that organ. Arch Surg. 10:1–72. 1925. View Article : Google Scholar
3	Kobayashi H, Sumimoto K, Moniwa N, et al: Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer. 17:37–43. 2007. View Article : Google Scholar : PubMed/NCBI
4	Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF and Robboy SJ: Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol. 20:133–139. 2001. View Article : Google Scholar : PubMed/NCBI
5	Yoshikawa H, Jimbo H, Okada S, et al: Prevalence of endometriosis in ovarian cancer. Gynecol Obstet Invest. 50(Suppl 1): 11–17. 2000. View Article : Google Scholar
6	Shih Ie M and Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 164:1511–1518. 2004.PubMed/NCBI
7	Park SY, Kwon HJ, Lee HE, et al: Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch. 458:73–84. 2011. View Article : Google Scholar : PubMed/NCBI
8	Martini M, Ciccarone M, Garganese G, et al: Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. Int J Cancer. 102:398–406. 2002.
9	Levanon D, Negreanu V, Bernstein Y, Bar-Am I, Avivi L and Groner Y: AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics. 23:425–432. 1994.PubMed/NCBI
10	Uno S, Zembutsu H, Hirasawa A, et al: A genome-wide association study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in Japanese. Nat Genet. 42:707–710. 2010. View Article : Google Scholar : PubMed/NCBI
11	Habtemariam B, Anisimov VM and MacKerell AD Jr: Cooperative binding of DNA and CBFβ to the Runt domain of the CBFα studied via MD simulations. Nucleic Acids Res. 33:4212–4222. 2005.
12	Li QL, Ito K, Sakakura C, et al: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 109:113–124. 2002. View Article : Google Scholar : PubMed/NCBI
13	Zaidi SK, Sullivan AJ, van Wijnen AJ, Stein JL, Stein GS and Lian JB: Integration of Runx and Smad regulatory signals at transcriptionally active subnuclear sites. Proc Natl Acad Sci USA. 99:8048–8053. 2002. View Article : Google Scholar : PubMed/NCBI
14	Subramaniam MM, Chan JY, Soong R, et al: RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat. 113:113–121. 2009. View Article : Google Scholar : PubMed/NCBI
15	Yoshizaki T, Enomoto T, Fujita M, et al: Frequent inactivation of RUNX3 in endometrial carcinoma. Gynecol Oncol. 110:439–444. 2008. View Article : Google Scholar
16	Dhillon VS, Shahid M and Husain SA: CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer. 3:332004. View Article : Google Scholar
17	Kato N, Tamura G, Fukase M, Shibuya H and Motoyama T: Hypermethylation of the RUNX3 gene promoter in testicular yolk sac tumor of infants. Am J Pathol. 163:387–391. 2003. View Article : Google Scholar : PubMed/NCBI
18	Cheng AS, Culhane AC, Chan MW, et al: Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res. 68:1786–1796. 2008. View Article : Google Scholar : PubMed/NCBI
19	Oxholm D, Knudsen UB, Kryger-Baggesen N and Ravn P: Postmenopausal endometriosis. Acta Obstet Gynecol Scand. 86:1158–1164. 2007. View Article : Google Scholar : PubMed/NCBI
20	Scott RB: Malignant changes in endometriosis. Obstet Gynecol. 2:283–289. 1953.
21	Jones PA: The DNA methylation paradox. Trends Genet. 15:34–37. 1999. View Article : Google Scholar
22	Kulis M and Esteller M: DNA methylation and cancer. Adv Genet. 70:27–56. 2010. View Article : Google Scholar
23	Senthong A, Kitkumthorn N, Rattanatanyong P, Khemapech N, Triratanachart S and Mutirangura A: Differences in LINE-1 methylation between endometriotic ovarian cyst and endometriosis-associated ovarian cancer. Int J Gynecol Cancer. 24:36–42. 2014. View Article : Google Scholar : PubMed/NCBI
24	Zochbauer-Muller S, Fong KM, Maitra A, et al: 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res. 61:3581–3585. 2001.
25	Baylin SB and Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16:168–174. 2000. View Article : Google Scholar : PubMed/NCBI
26	Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002.PubMed/NCBI
27	Wang H, Feng Y, Bao Z, et al: Epigenetic silencing of KAZALD1 confers a better prognosis and is associated with malignant transformation/progression in glioma. Oncol Rep. 30:2089–2096. 2013.PubMed/NCBI
28	Falkenberry SS, Steinhoff MM, Gordinier M, Rappoport S, Gajewski W and Granai CO: Synchronous endometrioid tumors of the ovary and endometrium. A clinicopathologic study of 22 cases. J Reprod Med. 41:713–718. 1996.PubMed/NCBI
29	Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA and Buller RE: Simultaneously detected endometrial and ovarian carcinomas - a prospective clinicopathologic study of 74 cases: a Gynecologic Oncology Group study. Gynecol Oncol. 83:355–362. 2001. View Article : Google Scholar
30	Kurman RJ and Shih IeM: Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 27:151–160. 2008.PubMed/NCBI
31	Martin DC: Cancer and endometriosis: do we need to be concerned? Semin Reprod Endocrinol. 15:319–324. 1997. View Article : Google Scholar
32	Vigano P, Somigliana E, Chiodo I, Abbiati A and Vercellini P: Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis. Hum Reprod Update. 12:77–89. 2006. View Article : Google Scholar : PubMed/NCBI
33	Van Gorp T, Amant F, Neven P, Vergote I and Moerman P: Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol. 18:349–371. 2004.PubMed/NCBI
34	Rosenblatt KA and Thomas DB: Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev. 5:933–935. 1996.
35	Ren F, Wang D, Jiang Y and Ren F: Epigenetic inactivation of hMLH1 in the malignant transformation of ovarian endometriosis. Arch Gynecol Obstet. 285:215–221. 2012. View Article : Google Scholar : PubMed/NCBI
36	Suzuki M, Shigematsu H, Shames DS, et al: DNA methylation-associated inactivation of TGFβ-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer. 93:1029–1037. 2005. View Article : Google Scholar